1 / 19

Abbvie Stock Analysis – November 2018

Abbvie Stock Analysis – November 2018. Harsha Talakad Rajashekhara , Saraja Samant , Shalin Rajpara Presented November 13, 2018. About the company. Founded in 2013 as a spinoff of Abbot Labs and trading on NYSE with a market cap of $134.45 billion.

idalia
Télécharger la présentation

Abbvie Stock Analysis – November 2018

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abbvie Stock Analysis – November 2018 HarshaTalakadRajashekhara, SarajaSamant, ShalinRajpara Presented November 13, 2018

  2. About the company • Founded in 2013 as a spinoff of Abbot Labs and trading on NYSE with a market cap of $134.45 billion 14 manufacturing facilities in 5 countries 5 Year revenue CAGR of 10% 8 research facilities in 3 countries 1101 products on the market 29000 employees

  3. Portfolio and Market Data

  4. Macroeconomic Drivers

  5. Corporate Lifecycle • Company Trends • Decreasing revenue growth from a major revenue stream (Humira) • Modifications to existing formulas to expand their utility • New acquisitions and research partnerships • Significant number of drugs in the pipeline • A growth trend in earnings and revenue Revenue • Conclusion • We believe that Abbvie is at the precipice of growth and maturity stage Launch Growth Maturity Decline Timeline

  6. SWOT Analysis Strengths Weaknesses • Global reach: Products sold in 200+ countries • Robust Pipeline: 20 new drug approvals expected by end of 2020 • High dependence on Humira, Imbruvica and Mavyret • Highly Levered growth strategy can prove risky in case of an economic downturn Opportunities Threats • Leukemia drug market expected to grow to $12B by 2022 • High barriers of entry • Aging population • Patents and Litigations are a general threat in the pharmaceutical industry • Biosimilars tend to eat into drug sales

  7. Porters Five Forces Threat of Competition Bargaining power of suppliers Threat of Substitutes Barriers to entry Bargaining power of buyers • Expiring patents • Biosimilar drugs • High • Biosimilar drugs • Generic drugs • Major revenue streams patent protected • High • Large number of products sourced from a single supplier • Moderate • High fixed cost • Long drug development process • Supply chain development • High • Buyers have a low bargaining power in the drug market • Low

  8. Strategic Acquisitions Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Date: 4th March, 2015 Deal Size: $21 billion ImmuVen develops drugs to treat infectious diseases, cancer, and autoimmune disorders. Date: 1st January, 2014 Deal Size: Unspecified Stemcentrx develops therapies that cure and significantly improve survival for cancer patients. It provides disease specific treatments that attack tumors at the roots. Date: 28th April, 2016 Deal Size: $5.8 billion

  9. Product Pipeline

  10. Management Discussion and Analysis

  11. Financial Statistics (Amounts in USD)

  12. Comparable Company Analysis – DuPont Model

  13. Comparable Company Analysis – Valuation

  14. Discounted Cash Flow Analysis

  15. Recommendation

  16. Thank You

More Related